Metastatic Adenocarcinoma of the Gastroesophageal Junction (DBCOND0069248)

Identifiers

Synonyms

Metastatic Adenocarcinomas of the Gastroesophageal Junction / Metastatic Adenocarcinoma of the Gastro-Esophageal Junction

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Capecitabine	A nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer.	Thymidylate synthasetarget Thymidine phosphorylaseenzyme Cytidine deaminaseenzyme Liver carboxylesterase 1enzyme Cytochrome P450 2C9enzyme DNAtarget RNAtarget Albumincarrier Uridine phosphorylase 1enzyme Uridine phosphorylase 2enzyme Thymidylate synthasetarget
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.	Receptor tyrosine-protein kinase erbB-2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04517747	Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction	Ramucirumab Tipiracil Trifluridine	treatment	Not Available	completed
NCT02065765	International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer	Ramucirumab	Not Available	Not Available	no_longer_available